Diabetology internationalAug 27, 2026

Misuse of GLP-1 weight-loss drugs: moving from correct prescribing to effective weight loss

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Aug 29, 2026

Abstract

Inappropriate use of GLP-1 medications may lead to serious health consequences.

Reports indicate that serious health issues may arise from both the toxicity of GLP-1 medications and unsafe weight-loss practices.
Current efforts focus mainly on regulatory compliance rather than the medical appropriateness of weight loss methods.
Medical appropriateness entails evaluating the risks associated not only with medications but also with the overall safety of weight reduction.
Emerging concepts suggest that weight loss should be assessed for its nutritional and clinical impacts, not just its amount.
A shift in discussion is proposed to prioritize appropriate weight reduction practices alongside safe medication use.

Simplified

Glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor dual agonists have transformed obesity treatment, but their widespread use has been accompanied by increasing medically inappropriate use for weight loss. Current efforts to promote the appropriate use of GLP-1-based medications have largely focused on regulatory compliance related to off-label prescribing and illegal acquisition. However, recent reports of serious health consequences associated with inappropriate tirzepatide use suggest that these events may arise not only from the intrinsic toxicity of these medications but also from inappropriate dietary restriction and inadequate medical supervision during weight-loss attempts. We argue that inappropriate use should be understood from two complementary perspectives: regulatory appropriateness and medical appropriateness. Medical appropriateness encompasses not only drug-related risks but also the safety of weight reduction itself. Emerging concepts such as female underweight/undernutrition syndrome further emphasize that weight reduction should be evaluated not only by its magnitude but also by its nutritional and clinical consequences. We propose that the discussion surrounding GLP-1-based therapies should move beyond appropriate drug use toward appropriate weight reduction, regardless of whether weight loss is pursued to improve obesity-related health conditions or for cosmetic purposes.

Full Text

Full text is available at the source.

View Full Text ↗

Misuse of GLP-1 weight-loss drugs: moving from correct prescribing to effective weight loss

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief